menu search

Panavance Therapeutics Announces Positive Preclinical Data Demonstrating GP-2250 Single-Agent and Combination Activity for the Treatment of Ovarian Cancer

Panavance Therapeutics Announces Positive Preclinical Data Demonstrating GP-2250 Single-Agent and Combination Activity for the Treatment of Ovarian Cancer
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 GP-2250’s antineoplastic effects on ovarian cancer cells include inhibition of glycolysis via modulation of HK2 activity in addition to GAPDH and NFkB down regulation and expression and inhibition of HIF-1α induced VEGF secretion GP-2250, alone and in combination with poly ADP-ribose polymerases […] The post Panavance Therapeutics Announces Positive Preclinical Data Demonstrating GP-2250 Single-Agent and Co... Read More
Posted: Apr 17 2023, 12:05
Author Name: forextv
Views: 091983

Search within

Pages Search Results: